Screening for cervical cancer: Will women accept less?
Background
U.S. professional organizations increasingly agree that most women require Papanicolaou smear screening every 2 to 3 years rather than annually and that most elderly women may stop screening. We sought to describe the attitudes of women in the United States toward less intense screening, specifically, less frequent screening and eventual cessation of screening.
Methods
We conducted a random-digit-dialing telephone survey of women in 2002 (response rate of 75% among eligible women reached by telephone). A nationally representative sample of 360 women aged 40 years or older with no history of cancer was surveyed about their acceptance of less intense screening.
Results
Almost all women aged 40 years or older (99%) had had at least one Pap smear; most (59%) were screened annually. When women were asked to choose their preferred frequency for screening, 75% preferred screening at least annually (12% chose screening every 6 months). Less than half (43%) had heard of recommendations advocating less frequent screening. When advised of such recommendations, half of all women believed that they were based on cost. Sixty-nine percent said that they would try to continue being screened annually even if their doctors recommended less frequent screening and advised them of comparable benefits. Only 35% of women thought that there might come a time when they would stop getting Pap smears; of these, almost half would not stop until after age 80 years. The strongest predictor of reluctance to reduce the frequency of screening was a belief that cost was the basis of current screening frequency recommendations.
Conclusion
Most women in the United States prefer annual Pap smears and are resistant to the idea of less intense screening. Concern that cost considerations rather than evidence form the basis of screening recommendations may partly explain women’s reluctance to accept less intense screening.
Keywords: Pap smear screening , Test frequency , Knowledge and attitudes
Drs. Sirovich, Woloshin, and Schwartz are supported by Veterans Affairs Career Development Awards in Health Services Research and Development; Drs. Schwartz and Woloshin are also supported by Robert Wood Johnson Generalist Faculty Scholar Awards. This study was supported by grants from the Department of Defense Breast Cancer Research Program (DAMD17-96-MM-6712) and the National Cancer Institute (CA91052-01). This study was also supported in part by a Research Enhancement Award from the Department of Veterans Affairs (03-098). The views expressed herein do not necessarily represent the views of the Department of Veterans Affairs or the United States Government.
PII: S0002-9343(04)00668-0
doi:10.1016/j.amjmed.2004.08.021
© 2005 Elsevier Inc. All rights reserved.

